Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas.
Autor: | Makino Y; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA fithege@mdanderson.org ymakino@mdanderson.org.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Rajapakshe KI; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Chellakkan Selvanesan B; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Okumura T; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Date K; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Dutta P; Cancer Systems Imaging, UTMDACC, Houston, Texas, USA., Abou-Elkacem L; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Sagara A; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Min J; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Sans M; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Yee N; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Siemann MJ; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Enriquez J; Cancer Systems Imaging, UTMDACC, Houston, Texas, USA., Smith P; Cancer Systems Imaging, UTMDACC, Houston, Texas, USA., Bhattacharya P; Cancer Systems Imaging, UTMDACC, Houston, Texas, USA., Kim M; Surgical Oncology, UTMDACC, Houston, Texas, USA., Dede M; Bioinformatics & Computational Biology, UTMDACC, Houston, Texas, USA., Hart T; Bioinformatics & Computational Biology, UTMDACC, Houston, Texas, USA.; Department of Cancer Biology, UTMDACC, Houston, Texas, USA., Maitra A; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA., Thege FI; Translational Molecular Pathology, UTMDACC, Houston, Texas, USA fithege@mdanderson.org ymakino@mdanderson.org.; Sheikh Ahmed Center for Pancreatic Cancer Research, UTMDACC, Houston, Texas, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Gut [Gut] 2024 Dec 10; Vol. 74 (1), pp. 75-88. Date of Electronic Publication: 2024 Dec 10. |
DOI: | 10.1136/gutjnl-2024-332412 |
Abstrakt: | Background: Oncogenic 'hotspot' mutations of KRAS and GNAS are two major driver alterations in intraductal papillary mucinous neoplasms (IPMNs), which are bona fide precursors to pancreatic ductal adenocarcinoma. We previously reported that pancreas-specific Kras G12D and Gnas R201C co-expression in p48 Cre ; Kras LSL-G12D ; Rosa26 LSL-rtTA ; Tg (TetO-Gnas R201C ) mice ( 'Kras;Gnas ' mice) caused development of cystic lesions recapitulating IPMNs. Objective: We aim to unveil the consequences of mutant Gnas R201C expression on phenotype, transcriptomic profile and genomic dependencies. Design: We performed multimodal transcriptional profiling (bulk RNA sequencing, single-cell RNA sequencing and spatial transcriptomics) in the 'Kras;Gnas ' autochthonous model and tumour-derived cell lines ( Kras;Gnas cells), where Gnas R201C expression is inducible. A genome-wide CRISPR/ Cas 9 screen was conducted to identify potential vulnerabilities in Kras G12D ;Gnas R201C co-expressing cells. Results: Induction of Gnas R201C -and resulting G Conclusion: Multiple orthogonal approaches demonstrate that Kras G12D and Gnas R201C co-expression results in a gene signature of gastric pyloric metaplasia and glycolytic dependency during IPMN pathogenesis. The observed metabolic reprogramming may provide a potential target for therapeutics and interception of IPMNs. Competing Interests: Competing interests: AM is listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. AM serves as a consultant for Tezcat Biosciences. (© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.) |
Databáze: | MEDLINE |
Externí odkaz: |